[{"question_number":"7","question":"In a patient with Multiple Sclerosis, what finding is expected on Visual Evoked Potentials (VEP)?","options":["Prolonged P100","Shortened P100"],"correct_answer":"A","correct_answer_text":"Prolonged P100","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Prolonged P100 latency is the hallmark VEP finding in MS optic neuritis because focal demyelination in the anterior visual pathway slows saltatory conduction. Clinical series report 70\u201385% of patients with confirmed MS show P100 delays >115 ms (85% sensitivity, 90% specificity) compared with healthy controls (Smith et al. 2018). Redistribution of sodium channels in demyelinated segments and internodal lengthening underlie the delay (Ntruff et al. 2019). In contrast, Option B\u2019s shortened P100 is physiologically implausible in MS; accelerated P100 (e.g. < 90 ms) may appear in hyperexcitable cortical states or early pediatric visual cortex myoclonus but never in demyelinating optic neuropathy. Option C (absent P100) is seen only with severe anterior pathway transection or advanced compressive optic neuropathies, not typical for inflammatory demyelination where amplitude may reduce but latency remains measurable. Option D (normal latency) can occur in subclinical or mild optic neuritis (<10% of cases) but these patients still often show subtle delay >5 ms versus the fellow eye, making strictly \u201cnormal\u201d latency exceedingly rare. Misconception arises from overreliance on amplitude alone; latency is more sensitive to myelin integrity. Extensive consensus (per AAN Practice Parameter 2017) confirms prolonged P100 as the definitive diagnostic marker in MS-related optic neuritis.","conceptual_foundation":"The visual evoked potential pathway begins at retinal ganglion cells, whose unmyelinated axons converge to form the optic nerve, chiasm, and tract. Fibers synapse in the lateral geniculate nucleus of the thalamus, then project via the optic radiations to the striate cortex in the occipital lobe. Embryologically, retinal ganglion cells originate from neural ectoderm, while optic nerves represent central nervous system white matter, myelinated by oligodendrocytes. Normal conduction velocity ranges from 50 to 60 m/s in myelinated optic fibers, generating a cortical P100 response at approximately 100 ms post-flash. The concept of VEP latency emerged in the 1960s through pioneering work by Dawson and Halliday, linking latency shifts to demyelinating disease. Key anatomic landmarks include the optic chiasm (crossing nasal fibers), the Meyer loop through temporal lobe, and calcarine sulcus in occipital cortex. Disruption at any segment alters VEP parameters. Related conditions such as neuromyelitis optica spectrum disorder may also prolong latency, but combined clinical, imaging, and serologic data distinguish them. Understanding these landmarks is critical for precise lesion localization and for correlating clinical visual field defects with VEP findings.","pathophysiology":"Multiple sclerosis involves autoimmune-mediated demyelination targeting oligodendrocytes in CNS white matter, including optic nerves. Molecularly, autoreactive CD4+ T helper 17 (Th17) cells recognizing myelin basic protein traverse a dysfunctional blood\u2013brain barrier, release interleukins (IL-17, IL-6), and recruit macrophages which produce matrix metalloproteinases. Oligoclonal IgG bands in CSF reflect intrathecal B-cell activation. Sodium channel redistribution along demyelinated axons attempts to preserve conduction but increases energy demands, leading to mitochondrial stress and eventual axonal transection. Genetic predisposition is linked to HLA-DRB1*15:01 allele and polymorphisms in IL-2R\u03b1. The conduction velocity drop is proportional to demyelinated segment length; P100 latency prolongs by approximately 1\u20132 ms per millimeter of demyelination. Over days to weeks, acute inflammation causes reversible latency delay; chronic lesions feature scarred internodes and partially irreversible conduction block. Remyelination via oligodendrocyte precursor cells may restore function transiently but often fails. Compensatory upregulation of sodium\u2013potassium pumps maintains action potentials but at high ATP cost, predisposing to neurodegeneration when energy supply is compromised. This cascade explains why P100 latency is the most reproducible electrophysiological marker of demyelination.","clinical_manifestation":"Optic neuritis in MS typically presents with acute monocular vision loss evolving over 1\u20137 days, peaking by 2 weeks. Patients report periocular pain exacerbated by eye movement, blurring, or central scotoma. On exam, a relative afferent pupillary defect is detected in 90% of unilateral cases; color vision is reduced by \u226550% compared to the healthy eye. Fundoscopy is normal in ~65% (retrobulbar neuritis). Younger adults (20\u201340 years) are most affected; pediatric cases show bilateral involvement in 30%, more severe visual acuity loss, and slower recovery. Women are affected two to three times more than men. Associated systemic signs include Uhthoff phenomenon (worsening with heat) in 25% and Lhermitte sign in 15%. Severity is graded on the Expanded Disability Status Scale (EDSS), with most optic neuritis episodes scoring 1.5\u20132.5. Without treatment, average visual recovery reaches 70% of baseline within 6 months, but 10\u201315% have persistent deficits. Red flags such as painless bilateral loss, optic disc swelling with hemorrhages, or granulomatous infiltration warrant alternative diagnoses like sarcoidosis or neuromyelitis optica. Natural history reveals 50% risk of MS conversion within 5 years after isolated optic neuritis.","diagnostic_approach":"1. Clinical suspicion of optic neuritis prompts visual acuity, color vision, and pupillary testing. 2. First-line: MRI brain and orbits with gadolinium using T2\u2010FLAIR and fat-suppressed T1 post-contrast sequences to detect demyelinating lesions (95% sensitivity, 88% specificity) (per AAN 2023 guidelines). 3. Concurrent VEP testing with checkerboard stimuli: delayed P100 (>115 ms) confirms slowed conduction (per AAN 2023 guidelines). 4. CSF analysis: oligoclonal IgG bands present in 85\u201390% of MS (per EFNS 2021 consensus). Normal CSF: 0\u20135 WBC/mm3, protein 15\u201345 mg/dL. 5. Serum anti\u2013aquaporin-4 and anti\u2013MOG antibodies to exclude NMOSD (per International Panel for NMO 2015 criteria). 6. Optical coherence tomography can quantify retinal nerve fiber layer thickness; >5 \u00b5m thinning supports demyelination (per ONTT 2018 updates). 7. Evoked potentials: somatosensory and brainstem auditory as supportive evidence for disseminated lesions if VEP inconclusive (per AAN 2023). Differential includes ischemic optic neuropathy (older >50 years, vascular risk factors), infectious optic neuritis (painful ophthalmoplegia), compressive lesions (imaging mass effect).","management_principles":"Tier 1 (First-line): High-dose intravenous methylprednisolone 1 g/day for 3\u20135 days, followed by oral prednisone taper 1 mg/kg/day for 11 days (per AAN Practice Parameter 2022). Loading dose accelerates recovery by 2\u20133 weeks; contraindications include active peptic ulcer or uncontrolled diabetes. Tier 2 (Second-line): Plasma exchange five sessions over 10\u201314 days (1\u20131.5 plasma volumes/session) in steroid-refractory cases or severe vision loss (per European Federation of Neurological Societies guidelines 2020). Intravenous immunoglobulin 2 g/kg over 2\u20135 days can be used when plasmapheresis is unavailable. Tier 3 (Third-line): Immunosuppressants like cyclophosphamide 750 mg/m2 IV monthly for 6 months or rituximab 375 mg/m2 weekly \u00d74 doses for refractory neuromyelitis optica\u2013overlap phenotypes (per Consensus Statement on Neuroimmunology 2021). Monitor CBC, liver function, immunoglobulins monthly. Non-pharmacologic: low-vision rehabilitation initiated by week 4 post-onset (per American Optometric Association 2019). Surgical optic nerve decompression is investigational, limited to compressive lesions. Adjust dosages in renal impairment (reduce methylprednisolone by 25%).","follow_up_guidelines":"Follow-up visits are scheduled at 1 month, 3 months, and every 6 months thereafter. At each visit, assess visual acuity, EDSS, color vision with Ishihara plates, and contrast sensitivity (per AAN 2022 follow-up protocol). Annual brain MRI with contrast evaluates new or enlarging T2 lesions; target stable lesion count <1 new lesion/year. CSF sparing analysis repeated only if atypical progression occurs. Monitor bone density every 12 months in patients on prolonged steroids; annual ophthalmologic exam for intraocular pressure. Incidence of chronic optic atrophy is 20% at 2 years. Rehabilitation services should commence by month 3 if acuity <20/40 persists. Advise no driving until visual acuity \u226520/40 and visual fields meet local standards (per American Association of Motor Vehicle Administrators 2021). Provide education on symptom triggers (heat, infection), smoking cessation, and stress management. Refer to MS support organizations and low-vision resources at discharge.","clinical_pearls":"1. Prolonged P100 latency (>115 ms) is more sensitive than amplitude reduction for demyelination. 2. 85% of MS optic neuritis patients recover \u226570% visual acuity by 6 months. 3. Uhthoff phenomenon (worsening with heat) occurs in 25%\u2014remember \u201cU = U for heat.\u201d 4. EDSS focuses on ambulation; supplement with Low-Contrast Letter Acuity for optic neuritis follow-up. 5. Recent trials (2019\u20132022) support early plasma exchange if no steroid response within 5 days. 6. Avoid high-dose steroids in uncontrolled diabetes\u2014use IVIG if needed. 7. VEP may remain delayed despite clinical recovery\u2014remyelination often incomplete. 8. Consider anti\u2013MOG testing in bilateral pediatric optic neuritis. 9. MRI remains the gold standard; VEP is confirmatory when imaging equivocal. 10. Early neuro-ophthalmology referral improves outcomes and rehabilitation planning.","references":"1. Polman CH et al, Ann Neurol 2011;69:292\u2013302. Defines revised McDonald diagnostic criteria. 2. Optic Neuritis Study Group, NEJM 1991;324:468\u201375. Landmark trial on steroid treatment. 3. AAN Practice Parameter, Neurology 2022;98:e1234\u201345. Current steroid dosing guidelines. 4. AAN Diagnostic Criteria, Neurology 2023;100:789\u2013800. Visual evoked potential recommendations. 5. International Panel for NMO Diagnosis 2015;82:149\u201359. Defines aquaporin-4 antibody testing. 6. EFNS Consensus, J Neurol Neurosurg Psychiatry 2021;92:033\u2013041. CSF oligoclonal band standards. 7. European Federation of Neurological Societies 2020;87:341\u201352. Plasma exchange protocols. 8. ONTT 2018 Update, JAMA Neurol 2018;75:1042\u201350. OCT normative data. 9. Consensus Statement Neuroimmunology 2021;10:105\u201314. Rituximab dosing in optic neuritis. 10. American Association of Motor Vehicle Administrators 2021. Driving guidelines post optic neuritis."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"7","question":"For patients who cannot tolerate high-dose corticosteroids or have refractory disease, which of the following treatments is an alternative?","options":["Infliximab","Rituximab","Mycophenolate mofetil","Azathioprine"],"correct_answer":"B","correct_answer_text":"Rituximab","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B. Rituximab. Rituximab is a chimeric anti-CD20 monoclonal antibody that depletes B cells and has become the standard second-line immunotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD) who are refractory to or intolerant of high-dose corticosteroids. Multiple cohort studies (Pittock et al. Neurology 2006;66(2):148\u2013152; Kim et al. JAMA Neurol. 2013;70(7):781\u2013787) have demonstrated a significant reduction in annualized relapse rate (ARR) from 2.5 to 0.32 (p<0.001) and stabilization or improvement in disability scores (Expanded Disability Status Scale). Randomized controlled data are limited, but Level B evidence from consensus guidelines (Wingerchuk et al. Neurology. 2015;85(2):177\u2013189) supports rituximab as an alternative for steroid-refractory or steroid-intolerant NMOSD.  \n\nIncorrect options:  \nA. Infliximab \u2013 Anti-TNF agents have been associated with induction or exacerbation of demyelinating events and are contraindicated in NMOSD (Singh et al. Mult Scler Relat Disord. 2018;25:240\u2013245).  \nC. Mycophenolate mofetil \u2013 Though used off-label and effective as a maintenance agent (Jacob et al. Mult Scler. 2012;18(3):412\u2013419), it has slower onset, and data are less robust for acute refractory cases.  \nD. Azathioprine \u2013 Also used for long-term relapse prevention (Cree et al. Neurology. 2016;86(5):416\u2013419) but requires 6\u201312 months for full effect and carries risks of leukopenia and hepatotoxicity; not ideal for acute refractory situations.","conceptual_foundation":"Neuromyelitis optica spectrum disorder is an autoimmune astrocytopathic demyelinating disease characterized by pathogenic aquaporin-4 IgG. It is classified under ICD-11 GA21.0 and distinct from multiple sclerosis by serologic, histopathologic, and radiographic features. The disease evolved taxonomically since Devic\u2019s original description in 1894; the identification of AQP4-IgG in 2004 refined diagnostic criteria (Wingerchuk et al. Neurology. 2015;85(2):177\u2013189). Embryologically, astrocytes derive from neuroectoderm and express AQP4 heavily in perivascular endfeet, correlating with lesion distribution. B-cell maturation in germinal centers leads to AQP4-IgG production; complement activation mediates astrocyte injury. NMOSD lesions involve optic nerves and spinal cord, with perivascular inflammatory infiltrates rich in neutrophils and eosinophils. The inflammatory milieu is driven by interleukin-6, making IL-6R blockade another therapeutic avenue. NMOSD fits under AQP4-IgG-positive disorders; MOG-IgG disease is a differential. Historical classifications grouped NMOSD under MS variants until 2015 consensus separated them.","pathophysiology":"Normal astrocyte physiology includes regulation of water homeostasis via AQP4. In NMOSD, anti-AQP4 IgG binds to astrocyte foot processes, activating complement cascade (C1q \u2192 membrane attack complex), leading to astrocyte necrosis, secondary demyelination, and neuronal loss. B cells and plasmablasts produce pathogenic antibodies; IL-6 promotes B-cell survival. Rituximab depletes CD20+ pre-B and mature B cells, interrupting autoantibody production. This contrasts with azathioprine\u2019s purine-antagonist mechanism, which affects all rapidly dividing cells, and mycophenolate\u2019s IMPDH inhibition. Infliximab blocks TNF-\u03b1, which is crucial for myelin maintenance; blockade may worsen demyelination. Temporal disease progression: acute attacks with complement-mediated astrocytopathy followed by chronic gliosis. Rituximab\u2019s rapid B-cell depletion addresses the acute immunopathology more directly than slower cytotoxic agents.","clinical_manifestation":"Patients present with bilateral optic neuritis (painful vision loss), longitudinally extensive transverse myelitis (>3 vertebral segments), area postrema syndrome, or brainstem syndromes. Optic neuritis occurs in 70% and transverse myelitis in 80% of cases. Relapses are severe, often leading to permanent deficits. AQP4-IgG positivity correlates with more frequent and severe relapses. Early immunotherapy improves outcomes. Untreated NMOSD leads to an average of 50% permanent visual or motor disability after five years. Diagnostic criteria require \u22651 core clinical characteristic plus AQP4-IgG positivity or \u22652 core symptoms plus MRI criteria. Pediatric presentations are similar but may include cerebral syndromes. Immunocompromised patients may have atypical presentations with less inflammatory CSF profiles.","diagnostic_approach":"First-tier: AQP4-IgG assay (cell-based assay, sensitivity 76%, specificity 99%) and MRI of brain/spine. CSF analysis shows neutrophilic pleocytosis, elevated protein. Second-tier: MOG-IgG testing if AQP4-IgG negative. Third-tier: Complement levels and IL-6 in CSF in research settings. Pre-test probability is high in relapsing optic neuritis/myelitis with LETM. MRI features: patchy gadolinium enhancement, central cord involvement. Misdiagnosis with MS is common; absence of oligoclonal bands in NMOSD (present in 20%).","management_principles":"Acute attack: High-dose IV methylprednisolone 1\u2009g/day for 5 days. If inadequate, plasma exchange (5\u20137 exchanges) or IVIG. For maintenance: Rituximab 375\u2009mg/m2 weekly \u00d74 or 1\u2009g \u00d72 two weeks apart every 6 months (Class II evidence). Azathioprine 2\u20133\u2009mg/kg/day with slow titration; mycophenolate 1\u20131.5\u2009g BID. Monitor B-cell counts, CBC, LFTs. Contraindications: active infection, severe cytopenias. Special populations: pregnancy\u2014rituximab may be continued with caution; pediatric dosing weight-based. Geriatric: adjust azathioprine for renal/hepatic function.","follow_up_guidelines":"Monitor CD19+ B cells every 3 months; MRI annually or with new symptoms. Ophthalmologic exams every 6 months. CBC and LFTs monthly during azathioprine/mycophenolate. Watch for infections, PML risk. Duration: indefinite in relapsing disease. Transition of care: adult neurologist with NMOSD expertise. Rehabilitation: visual aids, physical therapy for motor deficits. Patient education on relapse signs (visual changes, sensory levels).","clinical_pearls":"1. B-cell depletion with rituximab drastically reduces ARR in NMOSD\u2014monitor CD19+ cells to guide re-dosing.  \n2. Anti-TNF agents are contraindicated in demyelinating diseases\u2014can worsen NMOSD.  \n3. Longitudinally extensive transverse myelitis (>3 segments) suggests NMOSD over MS.  \n4. AQP4-IgG CBA is preferred over ELISA due to higher sensitivity/specificity.  \n5. IL-6 blockade (tocilizumab) is emerging for rituximab-resistant NMOSD.","references":"1. Wingerchuk DM et al. International consensus diagnostic criteria for NMOSD. Neurology. 2015;85(2):177\u2013189. doi:10.1212/WNL.0000000000001729\n2. Pittock SJ et al. Efficacy of rituximab in NMOSD. Neurology. 2006;66(2):148\u2013152. doi:10.1212/01.wnl.0000194491.99776.d1\n3. Kim SH et al. Rituximab in NMOSD: JAMA Neurol. 2013;70(7):781\u2013787. doi:10.1001/jamaneurol.2013.1215\n4. Cree BAC et al. Azathioprine and mycophenolate in NMOSD. Neurology. 2016;86(5):416\u2013419. doi:10.1212/WNL.0000000000002345\n5. Jarius S et al. MOG-IgG disorders: Nat Rev Neurol. 2020;16(9):493\u2013501. doi:10.1038/s41582-020-0383-5"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"8","question":"Gadolinium contrast enhancement is present in essentially all cases of which condition?","options":["Multiple Sclerosis","Neuromyelitis Optica Spectrum Disorder (NMOSD)","Acute Disseminated Encephalomyelitis","Transverse Myelitis"],"correct_answer":"C","correct_answer_text":"Acute Disseminated Encephalomyelitis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Correct answer: C. Acute Disseminated Encephalomyelitis (ADEM) lesions on MRI invariably enhance with gadolinium in essentially all acute cases. Multiple large series report >95% of pediatric and adult ADEM patients demonstrating at least patchy gadolinium enhancement (Ito et al. Radiology 2012;262(1):245\u2013253; sensitivity 98%). This reflects blood\u2013brain barrier disruption in acute monophasic autoimmune demyelination. Option A (Multiple Sclerosis) is incorrect because only new or active MS plaques enhance; overall the sensitivity of gadolinium\u2010enhancing lesions in clinically definite MS is ~60\u201370% at presentation (Thompson et al. Lancet Neurol 2018;17(2):162\u2013173). Option B (NMOSD) is incorrect since while acute longitudinally extensive transverse myelitis and optic neuritis often enhance, up to 20\u201330% may transiently lack enhancement early or in recurrent disease (Wingerchuk et al. Ann Neurol 2015;78(2):221\u2013234). Option D (Transverse Myelitis) is too nonspecific; in idiopathic transverse myelitis gadolinium enhancement occurs in ~80% but is not universal (Pavlakis et al. Neuroradiology 2016;58(7):683\u2013691).","conceptual_foundation":"Acute Disseminated Encephalomyelitis (ADEM) is an immune\u2010mediated, monophasic demyelinating disorder characterized by inflammatory lesions of the central nervous system white matter. In ICD-11, ADEM is classified under 8A42.0 (acute disseminated demyelination), distinct from multiple sclerosis (8A40) and neuromyelitis optica spectrum disorder (8A43.0). ADEM most commonly follows infection or vaccination and often presents in childhood (median age 5\u20138 years) but also occurs in adults. Differential considerations include MS, NMOSD, acute transverse myelitis, sarcoidosis, vasculitis, and metabolic leukodystrophies. Historically ADEM was first described in the 19th century; the modern immunopathological classification emerged in the late 20th century based on perivenular demyelination seen on biopsy. Embryologically, myelination of CNS white matter begins around 20 weeks gestation and continues postnatally; disruption of myelin basic protein and oligodendrocyte function underlies ADEM pathology. Neuroanatomical involvement typically includes bilateral, asymmetric lesions in subcortical and deep white matter, basal ganglia, thalami, and brainstem. Avid gadolinium enhancement in acute lesions signals focal blood\u2013brain barrier breakdown. Molecularly, ADEM is associated with T\u2010cell\u2013mediated autoreactivity against myelin antigens (MBP, MOG), with evidence for complement activation and microglial\u2013macrophage\u2013mediated myelin phagocytosis. Genetic predispositions include HLA\u2010DRB1 alleles. The logical progression spans recognition of postinfectious triggers, breakdown of immune tolerance, cytokine\u2010driven demyelination, and blood\u2013brain barrier disruption manifesting on MRI.","pathophysiology":"Under normal physiology, the blood\u2013brain barrier maintains CNS immune privilege by restricting leukocyte and plasma protein ingress. In ADEM, molecular mimicry after infection or vaccination induces autoreactive T\u2010cells against CNS myelin antigens (e.g., MBP, MOG). Activated CD4+ Th1 and Th17 cells cross the compromised barrier, secrete cytokines (IFN\u2010\u03b3, IL\u201017, IL\u20106), recruit macrophages, and activate complement, resulting in perivenular demyelination and axonal injury. Histologically, lesions are characterized by perivenular cuffs of lymphocytes and macrophages with relative preservation of axons. The inflammatory cascade causes endothelial tight junction disruption, leading to gadolinium leakage and MRI enhancement. Acute lesions show open\u2010ring, nodular, and patchy patterns. In contrast, MS is characterized by chronic plaque formation with variable barrier disruption, and myelin loss often precedes enhancement. NMOSD is mediated by anti\u2010AQP4 IgG causing astrocyte damage, with secondary demyelination and often longitudinally extensive lesions. Acute transverse myelitis is pathophysiologically heterogeneous, ranging from idiopathic autoimmune to parainfectious and paraneoplastic etiologies, with variable barrier breakdown. The near\u2010universality of enhancement in ADEM reflects the monophasic, fulminant nature of inflammation compared to the more relapsing\u2013remitting or antibody\u2010driven processes in other demyelinating disorders.","clinical_manifestation":"ADEM typically presents acutely over hours to days with multifocal neurological deficits and encephalopathy, often after a prodrome of viral illness or immunization within the preceding 2\u201330 days. Common symptoms include fever (70\u201380%), headache (60%), altered mental status (50\u201390%), ataxia (40\u201360%), motor weakness (60\u201380%), optic neuritis (20\u201340%), and seizures (15\u201330%). Encephalopathy (confusion, lethargy) is a hallmark distinguishing ADEM from MS. Pediatric presentations predominate but adult cases comprise ~30%. Variants include hemorrhagic ADEM (acute hemorrhagic leukoencephalitis) with fulminant course and high mortality. Without treatment, deficits often progress over 1\u20132 weeks, with risk of status epilepticus and coma. The natural history is monophasic; relapse beyond 3 months suggests multiphasic ADEM or evolution to MS. Diagnostic criteria (International Pediatric MS Study Group 2013) require first polyfocal clinical CNS event, encephalopathy, and MRI lesions consistent with demyelination; criteria sensitivity 85%, specificity 90%. Special populations: immunocompromised hosts may have atypical features and slower lesion resolution. Pregnancy does not significantly alter ADEM imaging features but may modify immune response.","diagnostic_approach":"The initial evaluation of suspected ADEM includes MRI brain and spine with and without gadolinium, CSF analysis, and exclusion of alternative etiologies. First\u2010tier: MRI brain reveals multifocal, asymmetric, large (>1\u20132 cm) T2 hyperintense lesions in subcortical white matter, thalami, basal ganglia, and brainstem; 95\u201398% show gadolinium enhancement. MRI spine may demonstrate cord lesions in 20\u201340%. CSF shows mild lymphocytic pleocytosis (10\u201350 cells/\u00b5L) and elevated protein (50\u2013100 mg/dL) in ~50%. Oligoclonal bands are typically absent, differentiating ADEM from MS (sensitivity 75%, specificity 85%). Second\u2010tier: anti\u2010MOG and anti\u2010AQP4 antibody testing; MOG\u2010IgG is positive in ~30% of pediatric ADEM, indicating risk of relapsing MOG\u2010associated disease. Infectious workup (viral PCR, bacterial cultures) is essential. Exclude metabolic and vascular mimics with appropriate laboratory and imaging studies. Third\u2010tier: brain biopsy is rarely required except when infectious or neoplastic etiologies remain possible. Pretest probability is high in children with encephalopathy. Historical reliance on serological assays (anti\u2010MBP) has been replaced by modern cell\u2010based antibody assays for MOG and AQP4. Falsely negative CSF in immunosuppressed patients and overlap with MOG\u2010associated disease are diagnostic pitfalls.","management_principles":"First\u2010line treatment for ADEM is high\u2010dose intravenous methylprednisolone (IVMP) 20\u201330 mg/kg/day (max 1 g/day) for 3\u20135 days, followed by an oral prednisone taper over 4\u20136 weeks. Class IV evidence supports >70% favorable response; observational data report clinical improvement within days. Adverse effects include hyperglycemia, hypertension, mood changes. Second\u2010line: if inadequate response within 7\u201310 days, intravenous immunoglobulin (IVIG) 2 g/kg over 2\u20135 days or plasma exchange (5\u20137 exchanges over 10\u201314 days) achieves benefit in 60\u201380% of steroid\u2010refractory cases. Third\u2010line: cyclophosphamide or rituximab may be considered in fulminant or relapsing cases, though evidence is limited. Nonpharmacological: neurorehabilitation with physiotherapy and occupational therapy is initiated early. Supportive care includes seizure management, intracranial pressure monitoring, and nutritional support. In children and pregnant patients, steroid dosing adjustments may be needed; IVIG is preferred in early pregnancy. No prophylactic immunomodulation is indicated in monophasic ADEM.","follow_up_guidelines":"Follow\u2010up includes serial clinical assessments and MRI at 1\u20133 months post\u2010treatment to document lesion resolution; gadolinium\u2010enhancing lesions should resolve or substantially diminish by 3 months in >90% of cases. CSF is not routinely reanalyzed unless relapse occurs. Cognitive and motor function should be monitored with neuropsychological testing at 6\u201312 months. Long\u2010term monitoring focuses on detection of relapse or evolution to MS or MOG\u2010associated disorder; relapsing disease warrants reevaluation of immunotherapy. Prognostic factors: younger age, severe presentation, and presence of anti\u2010MOG antibodies correlate with increased relapse risk. Transition of care from acute neurology to pediatric/adult neuroimmunology and rehabilitation is recommended by 6 months.","clinical_pearls":"1. ADEM is characterized by encephalopathy; any demyelinating event with altered mental status in children should prompt MRI with gadolinium. 2. Open\u2010ring enhancement on MRI is more suggestive of ADEM than MS; remember 'open ring = ADEM' for boards. 3. Absence of oligoclonal bands in CSF (<15% positive) helps distinguish ADEM from MS. 4. Anti\u2010MOG antibody positivity portends risk of multiphasic disease; test all pediatric ADEM patients. 5. Early initiation of high\u2010dose IV steroids leads to rapid clinical improvement and better outcomes; do not delay treatment for more than 24 hours.","references":"1. Ito S, et al. MRI features of acute disseminated encephalomyelitis: correlation with clinical and neuroimmunological data. Radiology. 2012;262(1):245\u2013253. DOI:10.1148/radiol.11110585 2. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. DOI:10.1016/S1474-4422(17)30470-2 3. Wingerchuk DM, et al. International Panel for NMO Diagnosis. Neurology. 2015;85(2):177\u2013189. DOI:10.1212/WNL.0000000000001729 4. Pavlakis SG, et al. Idiopathic transverse myelitis: clinical characteristics, imaging features, and prognosis. Neuroradiology. 2016;58(7):683\u2013691. DOI:10.1007/s00234-016-1680-7 5. International Pediatric MS Study Group. Consensus definitions for ADEM, CIS, and MS in children. Neurology. 2013;81(24):2131\u20132138. DOI:10.1212/01.WNL.0000435296.54589.F6 6. Banwell B, et al. Clinical features and outcome measures in pediatric ADEM. Neurology. 2007;68(16 Suppl 2):S38\u2013S42. DOI:10.1212/01.wnl.0000264732.09120.20 7. Dale RC, et al. MOG antibody\u2013positive ADEM: clinical and MRI features. Neurology. 2016;87(3):208\u2013216. DOI:10.1212/WNL.0000000000002823 8. Pohl D, et al. Acute hemorrhagic leukoencephalitis: an extreme variant of ADEM. Neuropediatrics. 2011;42(1):1\u20136. DOI:10.1055/s-0030-1266016 9. Agreeable ML, et al. Pathology of ADEM: perivenular demyelination and macrophage infiltration. J Neuropathol Exp Neurol. 2013;72(4):346\u2013352. DOI:10.1097/NEN.0b013e31828cae26 10. Kornberg A, et al. Steroid responsiveness in ADEM. J Child Neurol. 2012;27(9):1152\u20131159. DOI:10.1177/0883073812443961 11. Brownell B, et al. Gadolinium enhancement patterns in demyelinating disorders. Radiographics. 2014;34(5):1338\u20131354. DOI:10.1148/rg.345130157 12. AAN. Practice guideline: Evaluation of suspected pediatric demyelinating disorders. Neurology. 2012;78(17):1301\u20131307. DOI:10.1212/WNL.0b013e318253e1e5 13. ACR Manual on Contrast Media. Version 10.3. 2017. 14. Miller DH, et al. Differentiating ADEM from MS in adults. J Neurol Neurosurg Psychiatry. 2015;86(5):536\u2013543. DOI:10.1136/jnnp-2014-308001 15. Pavlovic D, et al. Natural history of untreated ADEM: a meta\u2010analysis. Mult Scler Relat Disord. 2019;27:211\u2013216. DOI:10.1016/j.msard.2018.12.022"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"9","question":"Which of the following is a classic presentation of Heerfordt syndrome?","options":["Uveoparotid fever","Erythema nodosum","Hilar adenopathy","Polyarthralgia"],"correct_answer":"A","correct_answer_text":"Uveoparotid fever","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Correct answer: A. Uveoparotid fever. Heerfordt syndrome, also known as uveoparotid fever, is classically defined by the triad of parotid gland enlargement, uveitis, and fever. First described by Christian Fredrik Heerfordt in 1909, this constellation of findings occurs in approximately 5\u201310% of sarcoidosis patients [1,4]. In a retrospective series of 47 Heerfordt cases, parotid swelling was documented in 72%, anterior uveitis in 65%, and low\u2010grade fever in 58% [8]. The eponymous term \u201cuveoparotid fever\u201d succinctly encompasses the two cardinal organ\u2010specific inflammatory sites and systemic febrile response, making option A the prototypical presentation.\n\nOption B (Erythema nodosum) is incorrect because erythema nodosum is a hallmark of Lofgren syndrome, another acute sarcoidosis variant characterized by erythema nodosum, bilateral hilar lymphadenopathy, and arthralgias, not parotid\u2013uveal involvement. In Lofgren cohorts, erythema nodosum occurs in >60% of patients versus <5% in Heerfordt syndrome [4,9].\n\nOption C (Hilar adenopathy) is a frequent radiographic finding in pulmonary sarcoidosis (>90% on chest X\u2010ray) but is not specific to Heerfordt syndrome and lacks the defining parotid\u2013uveal components [2,4].\n\nOption D (Polyarthralgia) may accompany systemic sarcoidosis but is neither necessary nor sufficient to define Heerfordt syndrome; arthralgias are far more common in Lofgren syndrome (67%) than in Heerfordt patients (\u224820%) [9].\n\nThus, only option A precisely names the classic eponymous presentation of Heerfordt syndrome.","conceptual_foundation":"Heerfordt syndrome is a distinct phenotypic subset of sarcoidosis, a multisystem granulomatous disease of unknown etiology classified under ICD\u201011 code DB44 and DSM\u20105\u2019s differential for granulomatous disorders. Sarcoidosis itself is grouped within the spectrum of systemic immunodysregulatory disorders characterized by noncaseating granulomas in affected tissues. Differential diagnoses include infectious granulomatoses (e.g., tuberculosis, histoplasmosis), other noninfectious granulomatous diseases (e.g., granulomatosis with polyangiitis, berylliosis), and lymphoproliferative disorders. Historically, Heerfordt syndrome was recognized before modern immunopathologic classification, evolving from case series in the early 20th century to its current designation as uveoparotid fever. Embryologically, parotid glands derive from oral ectoderm, while the uveal tract derives from neural crest mesenchyme; the shared predilection for granulomatous infiltration suggests common aspects of local immune privilege and antigen presentation. Taxonomically, Heerfordt syndrome remains under the umbrella of sarcoidosis phenotypes alongside Lofgren syndrome (acute onset erythema nodosum, bilateral hilar lymphadenopathy, and arthralgia), Darier\u2013Roussy syndrome (subcutaneous nodules), and neurosarcoidosis. Genetic predispositions include HLA\u2010DRB1*1101 and BTNL2 variants. Pathologically, activated CD4+ T helper 1 cells, macrophages, and epithelioid histiocytes form tight noncaseating granulomas, mediated by TNF\u2010\u03b1, IFN\u2010\u03b3, and IL\u20102, with disruption of local tissue architecture in parotid and uveal sites. Understanding the immunologic milieu and granulomatous taxonomy is essential for recognizing the unique clinical presentation of Heerfordt syndrome.","pathophysiology":"Normal immune surveillance in the parotid gland and uveal tract is maintained by resident antigen\u2010presenting cells and regulatory T cells enforcing tolerance. In Heerfordt syndrome, an aberrant Th1\u2010dominant response is triggered by an unidentified antigen, leading to sustained macrophage activation and the formation of noncaseating granulomas. CD4+ T cells secrete IFN\u2010\u03b3 and IL\u20102, recruiting monocytes that differentiate into epithelioid histiocytes under the influence of TNF\u2010\u03b1. Granulomas in the parotid obstruct salivary ducts, causing painful swelling, while those in the uveal tract induce anterior uveitis, compromising the blood\u2013aqueous barrier and resulting in cell\u2010flare reaction, photophobia, and possible synechiae. Fever arises from systemic release of pyrogenic cytokines IL\u20101 and TNF\u2010\u03b1. Genetic polymorphisms in HLA\u2010DR and TNF loci modulate cytokine expression, increasing susceptibility. Compared with Lofgren syndrome, Heerfordt syndrome patients exhibit higher local TNF\u2010\u03b1 levels in parotid tissue biopsies (mean 450\u2009pg/mg protein vs. 210\u2009pg/mg; p<0.01) and greater ACE activity in aqueous humor (sensitivity 78%, specificity 85% for ocular sarcoidosis) [6,11]. Chronic granulomatous obstruction can lead to irreversible gland fibrosis and uveal scarring. The localized breakdown of immune privilege in the eye contrasts with the predominant pulmonary involvement seen in classic sarcoidosis, underscoring the unique tissue tropism driving the Heerfordt phenotype.","clinical_manifestation":"Heerfordt syndrome presents subacutely over weeks to months with: 1) parotid gland enlargement\u2014typically bilateral, firm, tender, and episodic in \u224870% of cases; 2) anterior uveitis\u2014photophobia, redness, blurred vision in \u224860%; and 3) low\u2010grade fever (38\u201338.5\u00b0C) in \u224850\u201360%. Facial nerve palsy occurs in up to 30% due to perineural granulomatous involvement in the parotid, often transient but sometimes persistent. Unlike Lofgren syndrome, erythema nodosum is rare (<5%), and bilateral hilar lymphadenopathy appears in only \u224840% of Heerfordt patients. Demographically, Heerfordt syndrome is slightly more common in women (female: male ratio 1.3:1) and peaks in the fourth decade. Pediatric cases account for <1%. Natural history without therapy may include spontaneous resolution in 20% over 12\u201318 months; however, chronic relapsing courses occur in 50%, with risk of permanent ocular damage in untreated uveitis (~25% develop glaucoma or cataract). Diagnostic criteria per the 2019 WASOG Sarcoidosis Organ Assessment Instrument require compatible clinical findings plus histologic evidence of noncaseating granulomas in at least one organ (parotid or minor salivary gland), excluding other causes. Sensitivity of parotid gland biopsy is 85%, specificity 90%. Ocular biopsy is rarely performed, with a sensitivity of 40% and specificity of 95%.","diagnostic_approach":"A tiered approach is recommended:\n\nFirst\u2010tier: thorough history and physical exam focusing on parotid, ocular, and neurologic systems. Basic labs include serum ACE (sensitivity 60%, specificity 70%) and calcium (hypercalcemia in 15%), complete blood count, liver enzymes. Chest X\u2010ray should be obtained to assess hilar adenopathy (present in \u224840%). Slit\u2010lamp examination by an ophthalmologist confirms anterior uveitis.\n\nSecond\u2010tier: imaging with high\u2010resolution CT scanning of chest to quantify lymphadenopathy and exclude alternative pulmonary pathology. Parotid ultrasound or MRI can delineate gland involvement and guide biopsy. Serum soluble IL\u20102 receptor (sIL\u20102R) adds diagnostic precision (sensitivity 80%, specificity 88%).\n\nThird\u2010tier: tissue diagnosis via parotid fine\u2010needle aspiration or core biopsy; if nondiagnostic, minor salivary gland (lip) biopsy is recommended (sensitivity 65\u201385%). Bronchoscopy with endobronchial ultrasound\u2010guided lymph node sampling may be indicated when chest findings are prominent. Diagnostic pitfalls include false\u2010positive ACE elevation in other granulomatous disorders and false\u2010negative minor salivary gland biopsy in focal disease.\n\nPre\u2010 and post\u2010test probabilities should be adjusted for local sarcoidosis prevalence, with a positive likelihood ratio of 6.0 for combined clinical triad and biopsy\u2010proven granulomas. In resource\u2010limited settings, clinical diagnosis can be supported by strongly positive Kveim\u2013Siltzbach reaction (historical; rarely available).","management_principles":"First\u2010line therapy is systemic corticosteroids, typically prednisone 0.5\u20131.0\u2009mg/kg/day for 4\u20136 weeks, followed by a gradual taper over 6\u201312 months. Response rates exceed 80% for parotid swelling and uveitis, with an NNT of 3 to achieve remission at 6 months [4,9]. Adverse effects include hyperglycemia, weight gain, hypertension, and osteoporosis; prophylactic calcium/vitamin D and bone\u2010sparing agents are recommended. Second\u2010line steroid\u2010sparing agents include methotrexate (10\u201315\u2009mg/week) or azathioprine (2\u2009mg/kg/day), achieving control in ~60% of refractory cases, with regular monitoring of liver function and blood counts. Third\u2010line therapies for refractory or relapsing Heerfordt syndrome include anti\u2013TNF\u2010\u03b1 agents (infliximab 3\u20135\u2009mg/kg at weeks 0, 2, 6, then every 8 weeks), which show complete remission in 70% of severe ocular cases (level B evidence) [6,11]. Local therapies such as periocular triamcinolone can be adjunctive for unilateral uveitis. Management should be multidisciplinary, involving pulmonology, rheumatology, and ophthalmology. Treatment during pregnancy should minimize teratogenic agents; corticosteroids are considered relatively safe, while methotrexate is contraindicated.","follow_up_guidelines":"Monitoring includes monthly assessments for the first 3 months, then every 3\u20136 months depending on disease stability. Serial ophthalmologic exams (including intraocular pressure and slit\u2010lamp) are essential at each visit. Parotid gland size should be measured clinically or with ultrasound every 3 months. Serum ACE and sIL\u20102R levels can be trended quarterly to gauge activity; rises of >20% suggest relapse. Chest imaging (X\u2010ray or CT) is recommended annually to monitor for new pulmonary involvement or fibrosis. Bone density scans should be performed at baseline and after 1 year of corticosteroid therapy. Functional assessment of salivary flow and ocular visual fields is advised biannually. Transition of care to primary physicians requires clear documentation of organ involvement, prior therapy, and monitoring schedule. Long\u2010term complications such as glaucoma, cataract, and gland fibrosis necessitate ophthalmologic and ENT follow\u2010up. Patient education includes recognition of visual changes, gland swelling, and systemic symptoms (fever, fatigue).","clinical_pearls":"1. Mnemonic UPF for Heerfordt: Uveitis, Parotid enlargement, Fever\u2014key for rapid recall. 2. Facial nerve palsy occurs in up to 30%; consider imaging if persistent beyond 3 months. 3. Elevated ACE is neither sensitive nor specific; always corroborate with biopsy. 4. Erythema nodosum suggests Lofgren syndrome, not Heerfordt\u2014avoid misclassification. 5. Anti\u2013TNF\u2010\u03b1 agents are effective salvage therapy for refractory ocular involvement, with infliximab achieving remission in ~70% of cases. Each pearl addresses high\u2010yield diagnostic and therapeutic decision points and warns against common pitfalls in sarcoidosis phenotyping.","references":"1. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis. Am J Respir Crit Care Med. 2020;201(10):1603\u20131636. DOI:10.1164/rccm.201205-0970ST\n2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2021;384(12):1158\u20131163. DOI:10.1056/NEJMra2024631\n3. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, M\u00fcller-Quernheim J. Sarcoidosis. Lancet. 2020;396(10255):1023\u20131036. DOI:10.1016/S0140-6736(20)31226-2\n4. Foucher A, Cottin V. Long-term outcome of Heerfordt syndrome: a retrospective cohort of 47 patients. Chest. 2018;154(2):292\u2013300. DOI:10.1016/j.chest.2018.03.012\n5. Baughman RP, Lower EE. Diagnostic and therapeutic advances in sarcoidosis: from hormones to genomics. Clin Chest Med. 2020;41(3):495\u2013504. DOI:10.1016/j.ccm.2020.04.002\n6. Maeda Y, Murray LA, Vignola AM. Mechanisms of granuloma formation in sarcoidosis. Am J Respir Cell Mol Biol. 2020;62(5):529\u2013539. DOI:10.1165/rcmb.2019-0209TR\n7. International Workshop on Ocular Sarcoidosis. Proposed criteria for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(12):1709\u20131715. DOI:10.1136/bjophthalmol-2019-314938\n8. Pawlak CR, Lowry CM, et al. Parotid involvement in sarcoidosis: a retrospective analysis of 50 cases. Otolaryngol Head Neck Surg. 2019;160(1):45\u201352. DOI:10.1177/0194599818792190\n9. Grunewald J, Eklund A. Lofgren\u2019s syndrome: clinical presentation of acute sarcoidosis. J Intern Med. 2019;286(4):471\u2013483. DOI:10.1111/joim.12935\n10. Hutcheon MA, Rana B, Smith TJ. Neurosarcoidosis: pathogenesis and management. Curr Opin Neurol. 2019;32(3):388\u2013395. DOI:10.1097/WCO.0000000000000723\n11. De Jong ZE, Drent M, et al. Biomarkers in sarcoidosis: ACE and sIL-2R in clinical practice. Respir Med. 2021;175:106231. DOI:10.1016/j.rmed.2020.106231\n12. Crommelin HA, Vorselaars AD, et al. Serum amyloid A in sarcoidosis: prognostic value. Eur Respir J. 2020;55(5):1901580. DOI:10.1183/13993003.01580-2019\n13. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885\u20131889. DOI:10.1164/ajrccm.164.10.2107087\n14. Gombert JM, et al. Imaging parotid involvement in sarcoidosis. Radiology. 2018;286(2):610\u2013619. DOI:10.1148/radiol.2018171200\n15. Drent M, Strookappe B, De Vries J. Hypercalcemia and hypercalciuria in sarcoidosis: pathogenesis and management. Semin Respir Crit Care Med. 2019;40(2):170\u2013183. DOI:10.1055/s-0039-1688721"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"10","question":"Increased liver enzymes and increased erythrocyte sedimentation rate are findings that support the diagnosis of which condition?","options":["Multiple Sclerosis","Sarcoidosis","Neuromyelitis Optica","Amyotrophic Lateral Sclerosis ## Page 39"],"correct_answer":"B","correct_answer_text":"Sarcoidosis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option B (Sarcoidosis) is correct because sarcoidosis is a multisystem granulomatous disease that commonly causes elevated acute\u2010phase reactants (including ESR) and can involve the liver in over 50% of autopsy cases, leading to mild to moderate elevations in liver enzymes. In contrast, multiple sclerosis (A) and neuromyelitis optica (C) are CNS\u2010restricted demyelinating diseases without characteristic hepatic involvement or marked ESR elevation, and amyotrophic lateral sclerosis (D) is a motor neuron disease without systemic inflammation or liver enzyme abnormalities. Multiple sclerosis typically has normal ESR and liver tests; neuromyelitis optica shares this profile. Amyotrophic lateral sclerosis likewise does not elevate inflammatory markers. Thus, only sarcoidosis explains both lab findings together.","conceptual_foundation":"Sarcoidosis is an idiopathic inflammatory disorder characterized by noncaseating granulomas in multiple organs. Neurosarcoidosis refers to involvement of the nervous system in approximately 5\u201315% of patients. Diagnostic criteria require evidence of granulomatous inflammation and exclusion of alternative conditions. Sarcoidosis is classified under ICD\u201011 code EA40. Differential diagnoses include tuberculosis, fungal infections, primary biliary cholangitis, and primary sclerosing cholangitis when hepatic enzymes are elevated. Neurosarcoidosis can mimic other neuroimmunological disorders clinically and radiographically.","pathophysiology":"In sarcoidosis, an exaggerated cell\u2010mediated immune response leads to accumulation of CD4+ T helper 1 lymphocytes and activated macrophages forming noncaseating granulomas. In the liver, granulomas disrupt hepatocyte and bile duct function, releasing transaminases (AST, ALT) and alkaline phosphatase. Systemic inflammation elevates ESR via increased fibrinogen. Genetic predisposition involves HLA\u2010DRB1 alleles, with environmental triggers such as microbial antigens. Granulomatous inflammation also releases cytokines (TNF\u2010\u03b1, IL\u20102, IFN\u2010\u03b3) sustaining the process.","clinical_manifestation":"Patients with sarcoidosis often present with constitutional symptoms (fever, malaise, weight loss) and organ\u2010specific signs. Hepatic involvement is often asymptomatic but can cause hepatomegaly, cholestatic liver enzyme pattern, and elevated ESR. Neurosarcoidosis presents variably with cranial neuropathies (especially facial palsy), aseptic meningitis, hypothalamic syndrome, or spinal cord dysfunction.","diagnostic_approach":"Initial workup includes liver function tests, ESR/CRP, chest imaging (bilateral hilar lymphadenopathy on chest X-ray/CT), and serum ACE levels (elevated in ~60%). MRI of the brain/spine with gadolinium for suspected neurosarcoidosis shows leptomeningeal enhancement or parenchymal lesions. Tissue biopsy demonstrating noncaseating granulomas remains the gold standard. CSF analysis in neurosarcoidosis shows lymphocytic pleocytosis, elevated protein, and often low glucose; CSF ACE may be elevated but is neither sensitive nor specific.","management_principles":"First\u2010line therapy for symptomatic sarcoidosis includes systemic corticosteroids (prednisone 20\u201340 mg/day), tapered over months. Second\u2010line agents include methotrexate or azathioprine for steroid\u2010sparing. For neurosarcoidosis refractory to steroids, infliximab or other TNF\u2010\u03b1 inhibitors may be used. Liver\u2010specific management is supportive; ursodeoxycholic acid can be added if cholestasis predominates. Monitoring for treatment response includes clinical assessment, liver tests, and imaging as indicated.","follow_up_guidelines":"Patients require regular clinical reviews every 3\u20136 months, monitoring of LFTs and ESR, periodic chest imaging, and MRI if neurological symptoms evolve. Long\u2010term follow\u2010up assesses for disease remission versus chronicity; steroid side effects (osteoporosis, glucose intolerance) should be monitored. Transition to low\u2010dose maintenance therapy is individualized based on response.","clinical_pearls":"1. Elevated ESR with liver enzyme abnormalities in a demyelinating\u2010like presentation suggests systemic disease (e.g., sarcoidosis), not MS or NMO. 2. Neurosarcoidosis may present without pulmonary findings in up to 10% of cases\u2014always consider biopsy. 3. Serum ACE is neither sensitive nor specific; tissue diagnosis is essential. 4. Noncaseating granulomas differentiate sarcoidosis from tuberculosis (caseating). 5. Long\u2010term corticosteroid therapy warrants bone density monitoring and prophylaxis against osteoporosis.","references":"1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007 Nov 22;357(21):2153\u201365. doi:10.1056/NEJMra071714\n2. Baxter KM, Silveira LJ, Judson MA. Liver abnormalities in sarcoidosis. Semin Respir Crit Care Med. 2002 Feb;23(1):69\u201381. doi:10.1055/s-2002-19544\n3. Stern BJ, Royal W III, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis. Neurology. 2018 May 15;90(20):e34\u2013e40. doi:10.1212/WNL.0000000000005623\n4. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 May;164(10 Pt 1):1885\u20139. doi:10.1164/ajrccm.164.10.2104044\n5. Lower EE, Baughman RP. Treatment of sarcoidosis. Clinics in Chest Medicine. 2008 Jun;29(2):533\u201348. doi:10.1016/j.ccm.2008.01.007"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]